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Prognostic Factors in Patients with Pathologic T1-2N1M0
Disease in Non-small Cell Carcinoma of the Lung
Katsunari Matsuoka, MD,* Shinichi Sumitomo, MD,† and Noriyuki Misaki, MD†
Introduction: Patients with stage II non-small cell lung carcinoma
(NSCLC) represent a heterogeneous subgroup with variable 5-year
survival rates. The influence of the type of lymph node involvement
on survival and recurrence was investigated.
Methods: A total of 128 consecutive patients who underwent
complete tumor resection and mediastinal lymph nodes dissection
for pT1-2N1M0 NSCLC between July 1991 and December 2003
were retrospectively reviewed.
Results: The overall 5-year survival of patients with T1-2N1M0
disease was 42.2%. Although pT status, histology, surgical proce-
dure, and adjuvant therapy did not affect survival for pT1-2N1M0
patients, the 5-year survival rate differed significantly according to
the type of lymph node involvement. The 5-year survival rate for
patients with main bronchial lymph node involvement, interlobar
and lobar lymph node involvement, and segmental bronchial lymph
node involvement was 19.7%, 39.8%, and 59.7%, respectively. The
survival curves of these three groups had significant differences.
Fifty-five patients had cancer recurrence, and the type of lymph node
involvement did not affect the pattern of cancer relapse.
Conclusions: In patients with stage II NSCLC, survival differs
according to the type of lymph node involvement: patients with only
segmental lymph node involvement have a better prognosis and the
disease seems to be at an early stage, whereas patients with main
bronchial lymph node involvement have a poorer prognosis, and
main bronchial lymph node involvement represents more advanced
disease. Patients with pN1 disease represent a heterogeneous group
that may be subdivided according to the level of the involved N1
station, not pT factor.
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The survival of patients after surgery for non-small celllung cancer (NSCLC) remains poor. Although patients
with pathological stage II (p)N1 NSCLC are considered to
have relatively early-stage disease, their 5-year survival rate
is reported to be only 30% to 50%,1–10 and, thus, the outcome
is still unsatisfactory. Only a few studies have focused on the
postoperative outcome of pN1 disease, probably because of
the relatively small number of patients. In the present study,
therefore, we reviewed our previous cases of pT1-2N1M0
NSCLC and attempted to identify the prognostic factors in
pN1 disease.
PATIENTS AND METHODS
Between July 1991 and December 2003, 1171 patients
with NSCLC underwent complete surgical resection at the
department of thoracic surgery, Japanese Red Cross Society
Wakayama Medical Center. Of these patients, 131 were
defined as having stage II pN1 disease pathologically. Three
patients were excluded from this investigation because they
had undergone only limited resection (segmentectomy in two,
wedge resection in one). We retrospectively reviewed the
clinical records of the remaining 128 patients. Because of the
retrospective and anonymous nature of this study, approval
from the institutional review board and individual consent
were not required. For clinical staging, all patients underwent
a physical examination, chest radiography, computed tomog-
raphy of the thorax, brain, and upper abdomen, bone scintig-
raphy, and fiberbronchoscopy preoperatively. Positron emis-
sion photography (PET) was not available in our institute
before 2003, and no patients underwent PET before opera-
tion. All of the patients underwent total dissection of the
regional lymph nodes (ipsilateral hilar and mediastinal lymph
nodes). The histological type of the tumor was determined
according to the World Health Organization classification.
Pathological staging was determined according to the inter-
national TMN staging system.11 All dissected lymph nodes
were classified according to anatomic location, using the
numbering system of Naruke and colleagues12: main bron-
chial (no. 10), interlobar (no. 11), lobar bronchial (no. 12),
and segmental bronchial (no. 13). Main bronchial and inter-
lobar lymph nodes were dissected by surgeons at the opera-
tion. Lobar bronchial and segmental bronchial lymph nodes
were separated from the resected specimens by surgeons at
the back table in the operation room.
The mean age of the patients (109 men, 19 women) was
67.7 years (range, 38–85 years). The histological classifica-
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tion was squamous cell carcinoma in 74 cases, adenocarci-
noma in 45, large-cell carcinoma in 7, and adenosquamous
cell carcinoma in 2. Thirty-three patients had T1 disease, and
95 patients had T2 disease. The surgical procedures em-
ployed for these patients were pneumonectomy in 28, bilo-
bectomy in 16, and lobectomy in 84. All patients were
divided into four groups according to the proximal end of
involved lymph nodes. Nineteen patients had main bronchial
lymph node involvement (N1m), 36 had interlobar lymph
node involvement without main bronchial lymph node in-
volvement (N1i), 35 had lobar bronchial lymph node involve-
ment without main bronchial and interlobar lymph node
involvement (N1l), and 38 had only segmental bronchial
lymph node involvement (N1s).
Eighteen patients received preoperative induction ther-
apy, including induction radiotherapy in 5 patients, induction
platinum-based chemotherapy in 3 patients, and induction
chemo-radiotherapy in 10 patients. Induction therapy was
done because of large tumor in 10 patients, hilar lymph node
swelling on chest CT in 6 patients, and suspicion of tumor
invasion to diaphragm and chest wall on chest CT in 2
patients. Forty-three patients received adjuvant therapy post-
operatively, including chemoradiotherapy in 14 patients (ra-
diation alone in 7 patients and chemotherapy alone in 1
patient) and oral administration of tegafur and uracil (UFT) in
35 patients (UFT after chemoradiotherapy in 6 patients and
UFT alone in 29 patients).
We defined locoregional recurrence as clinically or
radiographically evident disease in the hilum and mediasti-
num, the supraclavicular node, the bronchial stump, or ma-
lignant pleural or pericardial effusion, and we defined distant
recurrence as disease in the lung and outside the thorax.
Last actualization of survival data was done in January
2006. All patients except three were completely followed up.
The median follow-up period for survival patients was 49.0
months (5.6–170.8 months).
Survival rates were calculated by the Kaplan–Meier
method, and comparisons among the survival curves were
made using the log–rank test. Zero time was the date of
pulmonary resection, and the terminal event was death attrib-
utable to cancer, noncancerous causes, or unknown causes.
Counts were compared using the chi-square test and Fisher’s
exact test. Continuous data were compared using the Mann–
Whitney U test. Multivariate analysis of prognostic factors
was performed using the Cox proportional hazards model.
Differences were considered to be significant at p  0.05.
Statistical analysis was performed using the StatView 5.0
software package (SAS Institute Inc., Cary, NC).
RESULTS
For the 128 patients with N1 disease as a whole, the
cumulative postoperative survival at 5 years was 42.2%
(Figure 1). Various factors that were supposed to influence
the patients’ outcomes (sex, histology, pT factor, tumor size,
site of primary tumor, preoperative carcinoembryonic anti-
gen, induction therapy, adjuvant therapy, surgical procedure,
perioperative blood transfusion) were examined by univariate
survival analysis, using Kaplan–Meier methods and log–rank
test, but none of these factors were significantly related to
survival except for sex: female patients had significantly
better outcome than male patients (Table 1).
We then investigated the outcome of pN1 patients
according to the level of lymph node involvement (Figure 2).
The 5-year survival rates for N1m patients, N1i patients, N1l
patients, and N1s patients were 19.7%, 39.2%, 41.7%, and
59.7%, respectively. Because the survival curve for N1i and
N1l patients were almost the same, we divided the pN1
patients into three groups as follows; N1m, N1il, and N1s.
The survival curves of these three groups had significant
difference (log–rank test, N1m versus N1il; p  0.0473,
N1il versus N1s; p  0.0439). The survival curve for N1m
patients demonstrated no significant difference from the sur-
vival curve for patients with pT1-2N2M0 disease resected at
our institution during the same period (pT1-2N2M0; n 133,
5-year survival rate: 19.7% versus 32.1%, log–rank test: p 
0.2269).
Multivariate analysis showed that the level of N1 dis-
ease (N1m or other) and sex were the independent prognostic
factor for patients with pN1 disease (Table 2). The patients
with N1m disease had significant worse prognosis than did
patients with N1i, N1l, or N1s disease.
We then examined the prognostic value of the number
of involved lymph node stations. Eighty patients had single-
station involvement disease, and 48 patients had multiple-
station involved disease (two stations or more). Patients with
lymph node involvement of only one station had a signifi-
cantly better survival curve than did patients with multiple-
station involvement (5-year survival rate: 48.1% versus
30.9%, log–rank test: p  0.0134). Nevertheless, when N1s
disease, which comprised solely single-station involvement
and had a significantly good prognosis, was excluded from
this analysis, no significant difference was found between
patients with single-station involvement and those with mul-
tiple-station involvement (5-year survival rate: 40.7% versus
30.9%, log–rank test: p  0.1826).
The level of nodal involvement according to the lobe in
which the primary tumor was located is summarized in Table
FIGURE 1. Overall survival curve of pT1-2N1M0 patients.
Five-year survival rate is 42.2%.
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3. Although the levels of the involved lymph nodes were not
significantly correlated with the site of the primary tumor,
upper-lobe tumors tended to involve the main bronchial
lymph nodes (no. 10), and lower-lobe tumors tended to
involve to interlobar lymph nodes (no. 11).
Fifty-six patients (43.8%) suffered cancer recurrence
after surgery. Detailed data regarding recurrence were not
available for seven patients. Thirty-four patients had distant
recurrence, 18 had locoregional recurrence, and 4 had both
types of recurrence. Table 4 compares the patterns of recur-
rence according to the site of the involved lymph nodes. In
both diseases, distant metastasis tended to be the main pattern
of recurrence, rather than locoregional recurrence. The initial
sites of recurrence are shown in Table 5. The brain was the
most common site for distant recurrence, followed by the
lung and bone. The overall 5-year disease-specific survival
rate was 44.1%. The 5-year disease-specific survival rates for
the various groups according to the site of the involved lymph
nodes were 26.7% for N1m, 41.3% for N1i, 43.4% for N1l,
and 52.1% for N1s. N1m had the lowest 5-year disease-
specific survival rate, but this did not reach significance.
TABLE 1. Patients Characteristics and Results of Univariate





Male 109 35.8 0.0055
Female 19 76.9
Age (yr)
70 66 41.8 0.1550
70 62 43.6
T factor
T1 33 41.3 0.8351
T2 95 42.8
Surgical procedure








Done 18 34.4 0.7859
None 110 43.2
Postoperative treatment




5 64 43.2 0.5399
5 54 39.4
Blood transfusion
Done 20 41.7 0.6874
None 108 42.4
Tumor size (mm)
30 24 40.4 0.3026
30–50 46 50.2
50 54 37.7
FIGURE 2. Overall survival curve of pT1-2N1M0 patients
according to the proximal end of involved lymph nodes.
N1m, main bronchial lymph node involvement; N1i, interlo-
bar lymph node involvement without main bronchial lymph
node involvement; N1l, lobar bronchial lymph node involve-
ment without main bronchial or interlobar lymph node in-
volvement; N1s, segmental bronchial lymph node involve-
ment without main bronchial, interlobar, or lobar bronchial
lymph node involvement. Five-year survival rates for each
group were as follows: N1s, 59.7%; N1l, 41.7%; N1i,
39.2%; N1m, 19.7%.
TABLE 2. Multivariate Analysis (Cox Proportional Hazard
Model)
HR 95% CI p
Sex
Female 0.298 0.128–0.693 0.0049
Involved lymph nodes
No. 10 2.145 1.209–3.806 0.0091
TABLE 3. The Level of Nodal Involvement According to the
Lobe of Primary Tumors
Proximal End of Involved Lymph Node
Primary Site No. 10 LN No. 11 LN No. 12 LN No. 13 LN Total
Upper lobe 9 9 18 15 51
Middle lobe 2 1 3 0 6
Lower lobe 8 26 14 23 71
Total 19 36 35 38 128
p  0.0793
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DISCUSSION
The outcome of surgery for pN1 NSCLC is controver-
sial. So far, several prognostic factors have been suggested
for patients with stage II N1 NSCLC. In the current TMN
staging system, T1N1M0 and T2N1M0 diseases are subdi-
vided into stage IIA and IIB according to the pT factor.
Nevertheless, in the present study, the pT factor did not affect
the postoperative survival of patients with p stage II, N1
disease. Similarly, Yoshino et al.,6 Yano et al.,5 and Ferguson
et al.13 all have demonstrated no difference in the postoper-
ative survival between patients with pT1N1M0 and those
with pT2N1M0 disease. Some studies have shown that the
level of the involved lymph nodes affects the prognosis for
pN1 disease.1,2,3,5,8,10 For example, Naruke et al.14 have
reported better survival in patients with intrapulmonary or
peribronchial lymph node metastasis. Yano et al.5 also have
reported that hilar nodal involvement had a significantly
worse prognosis than did other N1 disease. Riquet et al.15
have documented a significant difference in postoperative
survival between patients with N1 disease and those with
involvement of different nodes. Van Velzen et al.2,7 also have
demonstrated that the 5-year survival rate of patients without
hilar node involvement was superior to that of patients with
hilar node involvement in pT1N1M0 disease and pT2N1M0
disease. In our study, we analyzed postoperative survival by
classifying pN1 disease into four groups according to the
proximal end of the involved lymph node sites: N1m, N1i,
N1l, and N1s. We found that the survival curve for pN1
patients could be divided into three groups according to the
postoperative outcome. Survival curves of N1m, N1il, and
N1s had significant differences. Lymph node metastasis may
progress according to lymphatic flow. Regarding lymphatic
flow, the lobar bronchial and interlobar lymph nodes were
downstream of segmental bronchial lymph nodes, and the
main bronchial lymph nodes were the lowest part of the N1
nodes. Therefore, the progress lung cancer and the prognosis
of patients with NSCLC may be different according to the
level of involved lymph nodes. In the progression of disease
as well as lymphatic flow, N1i and N1l disease are the
intermediate group between N1m and N1s disease. N1m may
represent more advanced disease, and N1s may represent
early disease. Indeed, patients with N1m have a poorer
prognosis, and patients with N1s have a better prognosis in
the current study.
Furthermore, the 5-year survival rate of patients with
N1m disease was only 19.7%, and their survival rate was
lower than that of patients with pT1-2N2M0 disease resected
at our institution during the same period. In agreement with
our results, Ueda et al.16 also have reported that the survival
rate of patients with hilar N1 disease was similar to that for
patients with N2 disease. Main bronchial lymph nodes were
located close to lower mediastinal lymph nodes, which were
classified as N2 nodes, and N1m disease seems to have a
similar biological behavior to N2 disease in the treatment of
lung cancer. Multivariate analysis also revealed that the level
of lymph node involvement was an independent prognostic
factor for pT1-2N1 disease.
Marra et al.,1 Sayer et al.,3 and Ueda et al.9 have
reported that patients with single-station involvement had a
better prognosis than did patients with multiple-station in-
volvement. Our univariate survival analysis demonstrated
that the number of involved stations was related to outcome:
patients with only one station involved had a better long-term
outcome than did patients with multiple-station involvement.
Nevertheless, in the 80 patients with single-station involve-
ment, 38 patients (45.7%) had N1s disease. When N1s dis-
ease, which comprised almost a half of the patients with
single-station involvement and had a significantly good prog-
nosis, was excluded from this analysis, no significant differ-
ence was found between patients with single-station involve-
ment and those with multiple-station involvement. Therefore,
the good outcome of patients with single-station involvement
may be attributable to the inclusion of patients with N1s,
which has a good prognosis.
All of these studies, including the present one, have
demonstrated that NSCLC patients with N1 disease constitute
a heterogeneous group that might be subdivided according to
the level of the involved N1 station, rather than by pT factor,
suggesting that different therapeutic approaches should be
adopted according to subgroup profile. In our study, the
patients who received postoperative adjuvant therapy had a
better 5-year survival rate than did the patients without
adjuvant therapy, although the difference of these groups did
not reach significance. Because the outcome of the patients
with pN1 disease remains poor, they may need the effective
adjuvant therapy to improve survival after resection. In par-
ticular, the patients with N1m had significantly poor outcome,
similar to pN2 disease. The patients with N1m should be
dealt with in the same way as those with pN2 disease.
TABLE 4. The Comparison in the Patterns of Recurrence
According to the Site of Involved Lymph Nodes





No. 10 5 3 2 10
No. 11 10 3 2 15
No. 12 11 5 0 16
No. 13 8 7 0 15
Total 34 18 4 56
TABLE 5. The First Site of Metastasis
Distant Cases Distant  Locoregional Cases
Brain 13 Lung  mediastinum 3




Other includes cervical lymph nodes (1), inguinal lymph node (1), adrenal grand
(1), kidney (1), and urinary bladder (1).
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